Skip to Content
Merck
  • GC-EI-MS analysis of fatty acid composition in brain and serum of twitcher mouse.

GC-EI-MS analysis of fatty acid composition in brain and serum of twitcher mouse.

Lipids (2014-09-12)
Assunta Zanfini, Elena Dreassi, Anna Berardi, Paola Piomboni, Elvira Costantino-Ceccarini, Alice Luddi
ABSTRACT

Globoid cell leukodystrophy or Krabbe disease is an inherited autosomal recessive disorder caused by mutations in the galactosylceramidase gene. The objective of the study was to present information about the fatty acid (FA) composition of the brain and serum of twitcher mice, a mouse model of Krabbe disease, compared to wild type, in order to identify biomarker of disease progression. We defined the FA profiles by identifying the main components present in serum and brain using GC-EI-MS analysis. The FA percentage composition was measured and data were analyzed considering the disease and the mouse age as experimental factors. Significant correlations were established, both in brain and in serum, in the fatty acid percentage composition of twitcher compared to wild type mice. The most abundant saturated fatty acid in brain was the palmitic acid (C16:0) with mean values significantly increased in twitcher mouse (p = 0.0142); moreover, three monounsaturated, three polyunsaturated (PUFA) and a plasmalogen were significantly correlated to disease. In the serum highly significant differences were observed between the two groups for three polyunsaturated fatty acids. In fact, the docosahexaenoic acid (C22:6n3c) content was significantly increased (p = 0.0116), while the C20 PUFA (C20:3n6c and C20:5n3c) were significantly decreased in twitcher serum samples. Our study shows a specific FA profile that may help to define a possible pattern that could distinguish between twitcher and wild type; these data are likely to provide insight in the identification of new biomarkers to monitor the disease progression and thereby permit the critical analysis of therapeutic approaches.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Lignoceric acid, ≥99% (GC)
Sigma-Aldrich
Myristic acid, Sigma Grade, ≥99%
Sigma-Aldrich
Palmitoleic acid, ≥98.5% (GC), liquid
USP
Palmitic acid, United States Pharmacopeia (USP) Reference Standard
Palmitic acid, European Pharmacopoeia (EP) Reference Standard
Supelco
Palmitic acid, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Sigma-Aldrich
Linolenic acid, ~70% (GC)
Supelco
Nonanoic acid, analytical standard
Supelco
Linolenic acid, analytical standard
Supelco
Palmitic acid, analytical standard
Sigma-Aldrich
Palmitic acid, ≥98% palmitic acid basis (GC)
Supelco
Myristic acid, analytical standard
Sigma-Aldrich
Linoleic acid, technical, 58-74% (GC)
Supelco
Linoleic acid, analytical standard
Sigma-Aldrich
Palmitic acid, ≥98%, FCC, FG
Sigma-Aldrich
Nonanoic acid, 96%
Sigma-Aldrich
Myristic acid, natural, ≥98.5%, FG
Sigma-Aldrich
Myristic acid, ≥95%, FCC, FG
Sigma-Aldrich
Myristic acid, ≥98.0% (GC)
Sigma-Aldrich
Nonanoic acid, ≥96%, FG
Sigma-Aldrich
Palmitic acid, ≥99%
Sigma-Aldrich
Linoleic acid, liquid, BioReagent, suitable for cell culture
Sigma-Aldrich
Linoleic acid, ≥99%
Supelco
Palmitoleic acid, analytical standard
Sigma-Aldrich
Palmitic acid, BioXtra, ≥99%
Sigma-Aldrich
Nonanoic acid, ≥97%
Sigma-Aldrich
Linolenic acid, ≥99%
Sigma-Aldrich
Palmitic acid, natural, 98%, FG
Supelco
Myristic acid, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Palmitic acid, Pharmaceutical Secondary Standard; Certified Reference Material